stock markets for traders. period
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LPTN is the real gem. 3 products in the pipeline; iSONEP is the ONE that may be a cure for wet AMD (no one drug on market or under development can do this); huge $500 million commitment from $PFE...
It's gonna go up, and go up huge...
$LPTN did offering in March at $1.10; here is no real sellers...
$LPTN: I expect to see the steady volume $ pps increase due to the iSONE's Phase trial renewal at the end of this month or at the beginning of August (judging by CEO words at the conference) & huge catalysis for share price at the announcement. This stock can easily move up for 50% with just 300K shares in volume.
possible... Pfizer, with its patents expiration issues, may acting fast on acquisitions...
good commentary:
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_L/threadview?m=tm&bn=48151&tid=4235&mid=4248&tof=2&frt=2
Currently available drugs Lucentis and Avastin, owned by Genentech of the Roche Group (RHHBY.PK), only treat the symptoms over an effective 30 - 60 days. iSONEP is much closer to a CURE, as evidenced by past studies. In the Phase I trial, the candidate met primary endpoints for tolerance and also indicated an ability to mitigate retinal thickness and regress lesion, among other significant biological effects. In 2 of the 15 patients, RPE detachment was completely resolved. Average reduction of the faucet was 76% - far better than what Lucentis and Avastin have shown.
What is critically important is that most drugs ONLY control symptoms. You name it appetite suppressants, cardiovascular drugs, anti cholesterol drugs, tranquilizers. most cancer drugs etc,etc, only control symptoms.
The fact that iSONEP in 2 of the 15 patients, RPE detachment was completely resolved is outstanding by any means of measurement and a critical advantage as iSONEP progresses to phase 11 .
FDA Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious diseases and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious diseases. Determining whether a disease is serious is a matter of judgment, but generally is based on whether the drug will have an impact on such factors as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one.
If iSONEP would come to market think fast track. I know thats what Pfizer and most longs on this board are thinking.
watch LPTN for the next few weeks...
$ANTH: I'll be out at 1.28... go,go, go... lol
My guess that conservative estimate should be around $2 in short term (as soon as they start Phase 2 again)
$LPTN: going to follow the $MRIC pattern
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77540124
Aegis initiated coverage on shares of Lpath (LPTN). They issued a buy rating on the stock and set a $6.00 price target.
http://www.aegiscap.com/upload/files/Aegis%20Capital%20Announcement%20-%20Head%20of%20Healthcare%20Equity%20Research%202.pdf
***********
http://seekingalpha.com/article/706891-weekly-stock-watch-week-of-july-9
[...]
Lpath, Inc. (LPTN.OB): Lpath is another stock that may be gearing up for a move back to the dollar mark, as they were cruising along earlier this year at prices over the dollar mark - supported by volume fluid enough to sustain those levels - until two proof-of-concept trials for iSONEP, PEDigree for the treatment of retinal pigment epithelium detachment ("RPE detachment" or "PED") and NEXUS, targeting Wet AMD, were halted earlier this year due to FDA compliance issues with Lpath's finish/fill contractor.
The announcement of the trial delay sent shares quickly south of the one dollar mark while a subsequent stock offering sent shares even further downward. LPTN has since started to rebound as investors take note of the fact that the expected trial re-starts could provide the catalyst needed to launch shares back to over a buck.
Before the trial delays, investors were keying into this small company's status as a recognized leader in the field of lipid-based therapeutics and were also quick to notice the interest of Pfizer, Inc (PFE), which jumped on board early on in development. Pfizer's interest could have been piqued when it became apparent that Lpath was, at least to date, the only company to have successfully developed monoclonal antibodies against bioactive lipids. The targeting of bioactive signaling lipids has been the subject of increased medical research over recent years and Lpath, with its ImmuneY2 platform, is the only company to yet take the technology as far along in development as it has.
The company's proprietary ImmuneY2 platform contains the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders. The market potential for this technology in treating a plethora of modern day illnesses and diseases, should it advance past the clinical stages, is huge, and Lpath is first applying its technology to the treatment of Wet AMD and cancer, both multi-billion dollar markets, and that could just be the beginning.
Through ImmuneY2, Lpath has developed a pipeline of two lead product candidates, iSONEP and ASONEP, with a third, Lpathomab, in earlier stages of development.
According to previous comments by company officials, the iSONEP trials should re-start in August, or at some other point during the third quarter of this year.
Although trial halts will make some investors nervous, there is no reason to believe that the temporary halt effects the potential of iSONEP in any way. In a statement issued by the company via press release at the time of the trial halt, Lpath stated that "it has taken appropriate steps to oversee Formatech's manufacturing in order to ensure product quality, it has suspended dosing as a precaution to ensure the continued safety of all patients in its clinical trials.
With that in mind, the current prices could be considered quite the bargain for potential LPTN investors, especially considering the continued investment by Pfizer.
Pfizer holds a limited first right of refusal for ASONEP in the treatment of cancer, but threw down a large sum of money to become a full partner for iSONEP. A significant up-front payment came with assurances that the full value of the deal could be worth as much as nearly half a billion dollars to Lpath, should certain milestones be met and should Pfizer decide to continue the relationship following the completion of the Phase II trials.
Additionally, if Pfizer were to stay on board during the iSONEP commercialization phase, then Lpath would be due double digit royalties on sales. It's largely assumed, however, that a full acquisition would take place well before that point as the ImmuneY2 technology would have been proven to work as advertised and could lead to multiple new and ground breaking treatments for Pfizer.
The full potential of Lpath's pipeline should not go unnoticed to investors, and with catalysts pending later this summer, this is a stock to watch for the duration of the current quarter.
[...]
****************************
http://pennystockhaven.com/lpath-inc-lptn-undervalued-investment-in-biotech-company/
[...]
3. Time is NOW
Time for the re-establishing the trials for the Lpath’s drug candidates is quickly approaching the edge. Company should initiate the iSONEP™’s Phase 2 at the end of June or as late as the beginning of August 2012.
LPTN shares are deeply discounted. We’re expecting the first catalysis in the share price during the next two weeks on the prospect of Phase 2 trial renewal. Nothing is holding LPTN back: from the recent public offering Lpath’s development initiatives has been funded for 18+ month; rumor of the potential takeover is started to circulate again.
Pfizer (NYSE:PFE), who committed $517.5 million to develop and commercialize iSONEPâ„¢, may come out with a takeover offer at any time. Biotech giants are always looking towards emerging companies that have made substantial progress in developing high risk/high reward projects. Instead of jeopardize own independent product development, those multi-billion biopharmas are working alongside potential buyout candidates.
On any successful Lpath’s outcome the Pfizer may acquire a part of the LPTN’s technologies or even the entire company in the blink of the eye. Think for a minute: why to even pay half-billion dollars for the product development and share double-digit royalties from the millions in revenues after a product commercialization if the entire company may be acquired at the fraction of these costs? For the Pfizer, $170 billion Company, a few hundred millions just a pocket change…
Lpath, with its market capitalization of minuscule $56 million and products target for the multi-billion dollar markets, can be easily taken over with the triple digits premium to the current share/price.
Here is our key-phase again: join us on Lpath’s journey before mainstream media blows this stock up.
[...]
$ANTH: holding it at .73 average... did accumulate for 2 weeks. lol
http://finance.yahoo.com/news/equity-briefing-upgrades-downgrades-july-142101494.html
Aegis initiated coverage on shares of Lpath (LPTN). They issued a buy rating on the stock and set a $6.00 price target.
LPTN: should be fun for at least two/three weeks...
SSH: Sunshine is rocketing on ASX: http://www.asx.com.au/asx/research/companyInfo.do?by=asxCode&asxCode=SHC
very impressive... http://www.lpath.com/the-science/ppg/
Grants:
NIH/NEI BRDG-SPAN $3,000,000
Commercialization of iSONEPâ„¢, a Humanized Monoclonal Antibody against the Bioactive Lipid Sphingosine-1-Phosphate for the Treatment of AMD and other Ocular Disorders
2R44-CA110298-04 Sabbadini (Principal Investigator) 6/09-5/12 $3,000,000.
Commercialization of ASONEPTM, a Humanized Monoclonal Antibody Against the Pro-angiogenic and Tumorigenic Bioactive Lipid, Sphingosine-1-Phosphate.
2R44EY018020-02 Sabbadini (Co-Investigator). 12/1/07-12/01/09 $1,439,264.
Sphingomab Mitigates the Multiple Pathologies of Age-Related Macular Degeneration.
1R43GM088956-01 Sabbadini (Co-Investigator). 9/1/09-3/31/10. $152,724.
Structure Based Design of Humanized Monoclonal Antibodies that Recognize Bioactive Lipids.
1R43CA132395-01A2 Sabbadini, (Co-Investigator) 7/1/09-6/31/10. $139,523.
Development of therapeutic monoclonal antibody to the bioactive lipid lysophosphatidic acid.
Publications:
Goldshmit Y, Matteo R, Sztal T, Ellett F, Frisca F, Moreno K, Crombie D, Lieschke GJ, Currie PD, Sabbadini RA, Pébay A. Blockage of lysophosphatidic acid signalling improves spinal cord injury outcomes. Am. J. Pathology. (in press), 2012.
Sabbadini R, Wojciak JM, Moreno K, Visentin B. Antibodies to bioactive lysophospholipids in Lysophospholipid Receptors: Signaling and Biochemistry ed. J. Chun, et al. John Wiley, 2012 (in press).
Ponnusamy S, Selvam SP, Mehrotra S, Kawamori T, Snider AJ, Obeid LM, Shao Y, Sabbadini R, Ogretmen B. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med. Jun 18. [Epub ahead of print], 2012.
Frisca F, Sabbadini RA, Goldshmit Y, Pebay A. Biological Effects of Lysophosphatidic Acid in the Nervous System. Int. Rev. Cellular and Mol. Biol. 2012;296:273-322, 2012.
Visentin B, Reynolds G, Sabbadini, R. Immunohistochemical detection of sphingosine-1-phosphate and sphingosine kinase-1 in human tissue samples. Methods Mol Biol. 2012;874:55-67, 2012.
Lukowski ZL, Min J, Beattie AR, Meyers CA, Levine MA, Stoller G, Schultz GS, Samuelson DA, Sherwood MB. Prevention of Ocular Scarring After Glaucoma Filtering Surgery Using the Monoclonal Antibody LT1009 (Sonepcizumab) in a Rabbit Model. J Glaucoma. 2011 Sep 22. [Epub ahead of print].
Fleming JK, Wojciak JM, Campbell MA, Huxford T. Biochemical and structural characterization of lysophosphatidic acid binding by a humanized monoclonal antibody. J Mol Biol. 2011 May 6;408 (3):462-76. Epub Mar 15.
Gu Y, Forostyan T, Sabbadini R, Rosenblatt J. Epithelial cell extrusion requires the sphingosine-1-phosphate receptor 2 pathway. J Cell Biol. 2011 May 16;193(4):667-76. Epub May 9.
Berdyshev EV, Gorshkova I, Usatyuk P, Kalari S, Zhao Y, Pyne NJ, Pyne S, Sabbadini RA, Garcia JG, Natarajan V. Intracellular S1P Generation Is Essential for S1P-Induced Motility of Human Lung Endothelial Cells: Role of Sphingosine Kinase 1 and S1P Lyase. PLoS One. 2011 Jan 31;6(1):e16571.
Sabbadini, RA. Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br J Pharmacol. 2010 Nov 22. [Epub ahead of print].
Wojciak, J., Zhu, N., Schuerenberg, K., Moreno, K., Shestowksy, W., Hiraiwa, M., Sabbadini, R., Huxford, T. The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen. Proc. Nat. Acad. Sci. 2009 Oct 20; 106(42):17717-22. Epub Oct 7 2009.
O'Brien, N., Jones, ST., Williams, DG., Cunningham, HB., Moreno, K., Visentin, B., Gentile, A., Vekich, J., Shestowsky, W., Hiraiwa, M., Matteo, R., Cavalli, A., Grotjahn, D., Grant, M., Hansen, G., Campbell, MA., Sabbadini, R. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res. 2009 50, 2245-2257, Epub Jun 9 2009.
Gellings Lowe, N., Swaney, JS., Moreno, K., Sabbadini, R. Sphingosine-1-phosphate and sphingosine kinase are critical for TGF-alpha-stimulated collagen production by cardiac fibroblasts. Cardiovascular Res. 2009 May 1; 82 (2):303-12. Epub Feb 19 2009.
Caballero, S., Moreno, K., Stoller, G., Cavalli, A., Garland, W., Hansen, G., Sabbadini, R., Grant, M. Anti-sphingosine-1-phosphate monoclonal antibody inhibits angiogenesis and sub-retinal fibrosis in a murine model of laser induced choroidal neovascularization. Experimental Eye Research 2009 Mar; 88(3):367-77. Epub Aug 6 2008.
Swaney, J., Moreno, K., Gentile, A., Sabbadini, R., Stoller, G. Sphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eye. Experimental Eye Research 2008 Oct;87(4):367-75. Epub Jul 18 2008.
Visentin, B., Vekich, J., Sibbald, B., Cavalli, A., Matteo, R., Moreno, K., Garland, W., Lu, Y., Xing, F., Kumar, V., Mills, G., Sabbadini, R. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9:225-238. 2006.
Presentations:
Invited Speaker and Session Chair at the FASEB Summer Conference Lysophospholipid Mediators in Health and Disease. Luca, Italy.
June 2011
Invited Keynote Speaker for the 6th Annual Protein Engineering Summit (PEGS). Boston, Massachusetts.
May 2011
Invited Speaker Experimental Biology meeting (Molecular Pharmacology division of the American Society of Pharmacology & Experimental Therapeutics), Anaheim, CA.
April 24-28, 2010
Plenary Speaker Bioactive Lipids in Cancer, Inflammation and Related Diseases in Cancun, Mexico
October 25-28, 2009
Invited talk at the Medical University of South Carolina, Department of Biochemistry and Molecular Biology Hollings Cancer Center.
October 15, 2009
Invited Speaker at FASEB Summer Conference on Lysophospholipid Mediators in Health and Disease, Carefree, AZ.
June 28, 2009
Invited Speaker INSERM and IPBS, Institut de Pharmacologie et de Biologie Structurale of the CNRS. Toulouse, France
May 24, 2009
Invited Speaker American Assoc. of Cancer Researchers (AACR) 100th annual meeting. Denver, CO
April 20, 2009
http://seekingalpha.com/article/711791-buyout-talk-catalysts-and-clinical-results-can-move-these-healthcare-stocks
Another company that may be in line to receive an offer before the approval process is complete is Lpath Inc. (LPTN.OB). Considering the potential catalysts in play and a prime-time partnership with Pfizer (PFE), Lpath shares may be undervalued right now.
Lpath has become a recognized leader in the field of developing lipid-based therapies through its proprietary ImmuneY2 platform, which contains the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders. The market potential for this technology in treating a plethora of modern day illnesses and diseases, should it advance past the clinical stages, is huge. Lpath is first applying this technology to treat Wet AMD and cancer, both multi-billion dollar markets, and that could just be the beginning.
Through ImmuneY2, Lpath has developed a pipeline of two lead product candidates, iSONEP and ASONEP, with a third, Lpathomab, in earlier stages of development. Two iSONEP trials were halted earlier this year, for reasons unrelated to the effectiveness or of the treatment, but both should be restarted within months, according to statements made by company officials, which provides a potential share price catalyst to join the perennial buyout talk surrounding Lpath as the result of the Pfizer deal.
Given the unique potential of Lpath's technology, it's possible that a Pfizer deal could materialize well before the final results of late stage trials are known - and significantly before an FDA approval determination is on the table - such is the nature of the game when big pharma is on the prowl.
http://seekingalpha.com/article/706891-weekly-stock-watch-week-of-july-9
Lpath, Inc. (LPTN.OB): Lpath is another stock that may be gearing up for a move back to the dollar mark, as they were cruising along earlier this year at prices over the dollar mark - supported by volume fluid enough to sustain those levels - until two proof-of-concept trials for iSONEP, PEDigree for the treatment of retinal pigment epithelium detachment ("RPE detachment" or "PED") and NEXUS, targeting Wet AMD, were halted earlier this year due to FDA compliance issues with Lpath's finish/fill contractor.
The announcement of the trial delay sent shares quickly south of the one dollar mark while a subsequent stock offering sent shares even further downward. LPTN has since started to rebound as investors take note of the fact that the expected trial re-starts could provide the catalyst needed to launch shares back to over a buck.
Before the trial delays, investors were keying into this small company's status as a recognized leader in the field of lipid-based therapeutics and were also quick to notice the interest of Pfizer, Inc (PFE), which jumped on board early on in development. Pfizer's interest could have been piqued when it became apparent that Lpath was, at least to date, the only company to have successfully developed monoclonal antibodies against bioactive lipids. The targeting of bioactive signaling lipids has been the subject of increased medical research over recent years and Lpath, with its ImmuneY2 platform, is the only company to yet take the technology as far along in development as it has.
The company's proprietary ImmuneY2 platform contains the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders. The market potential for this technology in treating a plethora of modern day illnesses and diseases, should it advance past the clinical stages, is huge, and Lpath is first applying its technology to the treatment of Wet AMD and cancer, both multi-billion dollar markets, and that could just be the beginning.
Through ImmuneY2, Lpath has developed a pipeline of two lead product candidates, iSONEP and ASONEP, with a third, Lpathomab, in earlier stages of development.
According to previous comments by company officials, the iSONEP trials should re-start in August, or at some other point during the third quarter of this year.
Although trial halts will make some investors nervous, there is no reason to believe that the temporary halt effects the potential of iSONEP in any way. In a statement issued by the company via press release at the time of the trial halt, Lpath stated that "it has taken appropriate steps to oversee Formatech's manufacturing in order to ensure product quality, it has suspended dosing as a precaution to ensure the continued safety of all patients in its clinical trials.
With that in mind, the current prices could be considered quite the bargain for potential LPTN investors, especially considering the continued investment by Pfizer.
Pfizer holds a limited first right of refusal for ASONEP in the treatment of cancer, but threw down a large sum of money to become a full partner for iSONEP. A significant up-front payment came with assurances that the full value of the deal could be worth as much as nearly half a billion dollars to Lpath, should certain milestones be met and should Pfizer decide to continue the relationship following the completion of the Phase II trials.
Additionally, if Pfizer were to stay on board during the iSONEP commercialization phase, then Lpath would be due double digit royalties on sales. It's largely assumed, however, that a full acquisition would take place well before that point as the ImmuneY2 technology would have been proven to work as advertised and could lead to multiple new and ground breaking treatments for Pfizer.
The full potential of Lpath's pipeline should not go unnoticed to investors, and with catalysts pending later this summer, this is a stock to watch for the duration of the current quarter.
http://hosted.verticalresponse.com/758873/08137c0593/1343027789/d1916f71c2/
As the conclusion in our research on the Sunshine Heart (SSH) we wrote:
Join us on Sunshine Heart's board before mainstream media blows this stock up.
SSH stock accomplished a remarkable run-up in just three trading session. SSH shares were tripled in price and only now, week later and Sunshine Heart’s stock retracements back for 30%, the mass media started to cover it.
Point is: be proactive, follow our research, and your account will boost in value on the upcoming market reaction for our new undervalued investment opportunity pick - Lpath, Inc. (LPTN)
1. Company and its products:
Lpath Incorporated
4025 Sorrento Valley Blvd.
San Diego, CA 92121
Tel: 858-678-0800
Fax: 858-678-0900
http://www.lpath.com/
Lpath, Inc. is a biotechnology company focused on the discovery and development of monoclonal antibodies targeted to bioactive lipids. Lipid-based therapeutics are an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases that currently lack innovative and effective medicines.
Lpath's ImmuneY2 platform contains the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders.
In this report we’d like to highlight Lpath’s iSONEP™ product candidate for the treatment of the wet Age-related Macular Degeneration (AMD).
Over 1.5 million Americans affected with this disease. At present time only drugs such as Lucentis® or Avastin® are available for the treatment. Medications are very expensive and required to be taken on a daily basis. Just imaging how inconvenient for the wet AMD patient to carry everywhere a container (drug must be kept at the particular temperature) with the daily medication quantity.
Moreover, the existing wet AMD drugs have serious side effects. For instance, the Lucentis® patients may have serious infections inside the eye, detached retinas, and cataracts. The most common non–eye-related side effects are nose and throat infections, headache, and respiratory (lung) infections. Although not common, Lucentis® patients have had eye- and non–eye-related blood clots (heart attacks, strokes, and death).
Even more, if children affected with wet AMD still have a chance to recover from this disease when their body develops an immune protection at the age of 18th or so, adults must take those medications for the entire life.
Lpath’s iSONEP™ is not only reduced the medication dose from the daily to once per week, not only eliminate the drug-related serious adverse events, but it also succeeded in a key positive biological effects. Will iSONEP™ be a cure for the wet AMD? Continuation of the iSONEP™ Phase II and subsequent studies will be answering to this question.
2. Series of Unfortunate Events
In January 2012, Lpath reported that it has temporarily suspended dosing patients in its PEDigree and Nexus (wet AMD) trials. The company has taken this action because FDA ceased the operation of the Formatech, Inc., LPTN's fill/finish contractor, for non-compliance with FDA's current Good Manufacturing Practice (cGMP) requirements. Lpath had to suspend its clinical trials as a precaution to ensure the continued safety of all patients. Manufacturer failure cost the Lpath and other Formatech’s clients not only money, but precious time to market as well. Leo Ehrlich, Cellceutix (CTIX) CEO and one of the former Formatech's customers, commented:
"The FDA invalidated our product. The manufacturing problems were not to do with our product. It’s a little like throwing the baby out with the bath water."
Anyhow, suspended trials and 6 month delay for finding an alternate fill/finish contractor caused negative market reaction on the LPTH stock: share price dropped for over 30%. A subsequent stock offering (6,482,978 shares with an exercise price of $1.10/share and 208,227 warrants, that were issued to the placement agents in the offering and to Griffin Securities, Inc., with an exercise price of $0.75/share) sent Lpath’s shares even further downward.
3. Time is NOW
Time for the re-establishing the trials for the Lpath’s drug candidates is quickly approaching the edge. Company should initiate the iSONEP™’s Phase 2 at the end of June or as late as the beginning of August 2012. LPTN shares are deeply discounted. We’re expecting the first catalysis in the share price during the next two weeks on the prospect of Phase 2 trial renewal.
Nothing is holding LPTN back: from the recent public offering Lpath’s development initiatives has been funded for 18+ month; rumor of the potential takeover is started to circulate again. Pfizer (NYSE:PFE), who committed $517.5 million to develop and commercialize iSONEP™, may come out with a takeover offer at any time.
Biotech giants are always looking towards emerging companies that have made substantial progress in developing high risk/high reward projects. Instead of jeopardize own independent product development, those multi-billion biopharmas are working alongside potential buyout candidates. On any successful Lpath’s outcome the Pfizer may acquire a part of the LPTN's technologies or even the entire company in the blink of the eye.
Think for a minute: why to even pay half-billion dollars for the product development and share double-digit royalties from the millions in revenues after a product commercialization if the entire company may be acquired at the fraction of these costs? For the Pfizer, $170 billion Company, a few hundred millions just a pocket change...
Lpath, with its market capitalization of minuscule $56 million and products target for the multi-billion dollar markets, can be easily taken over with the triple digits premium to the current share/price.
Here is the our key-phase again: join us on Lpath’s journey before mainstream media blows this stock up.
Best
PennyStockHaven Staff
Please note: PennyStockHaven.com reserves rights to buy or sell aforementioned security on open market and may liquidate it without any notice. See full disclaimer here
glad that you have enough funds to hold over today's hod...
$PROF > 0.33 > 0.25 x 0.34 > what's brewing?
impressive
$PROF > 2 X Form 4... look like a good candidate for a big promo...
$17
oh man, you're playing with the fire... IB is very restricted with the margins...
$SSH $17
$SSH $14.5 HOD
good trade buddy
$14 HOD
$SSH still over $12 > $13 HOD today
told ya
your total "short" pps is around $10... man, you are down $2 per share... feel sorry 4 u . lol
$13 HOD
I like this one: http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_S/threadview?m=tm&bn=140663&tid=57&mid=70&tof=1&frt=2
high volatility... may dip even more... whatever - $12 to $15 in a week or a few... could be more
$10.47 HOD...
margin call, buddy? lol
for all new investors here: SSH only ONE who has the solution for the Class III (moderate) heart failure on a market. eom
2.6M float > CE Mark approval in Europe news could be out any day now
$10.30 HOD
$SSH $9 HOD; weeeeeeeeeeeeeeeeeeeee
congrats buddy
target is at least $12
no problem
$8.12 HOD; should dip a bit now...